to be resistant to doxycycline, culture and susceptibility test are recommended. Because many strains of the following groups of microorganisms have been shown

Respiratory tract infections caused by Haemophilus influenzae.

Inability, they should be considered in selecting or modifying antibacterial therapy.

Inhalational Anthrax (Post-Exposure)

Psittacosis (ornithosis) caused by Chlamydophila psittaci.

Respiratory tract infections caused by Mycoplasma pneumoniae.

2.3 Inhalational Anthrax (Post-Exposure)

Because doxycycline in doses of 25 mg/kg of body weight may be given single daily dose or divided in two or more doses.

Rhizopus arrhizus, some strains of which are resistant to amphotericin B.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals

Because tetracyclines have been shown to depress plasma prothrombin activity.

neference can remain elevated for weeks after drug cessation patients should be

rumination (w ith marked overgrowth) in the enteric tract and may result in gas
dermal reactions, encephalopathy, and psychiatric reactions. (7.7)

Photosensitivit y manifested by an exaggerated sunburn reaction has been

Because tetracyclines have been shown to depress plasma prothrombin activity.

5.1 Tooth Development

Photosensitivity is discussed above [see Warnings and Precautions (5 3)].

6.2 Post-Market Experience

• Photosensitivity is manifested by an exaggerated sunburn reaction has been

4 CONTRAINDICATIONS

Doxycycline use during pregnancy or if the patient becomes pregnant while taking these

In severe acne, doxycycline may be useful adjunctive therapy.

Inclusion conjunctivitis caused by Chlamydia trachomatis.

Intracranial hypertension (IH, pseudotumor cerebri) is a rare but serious complication.

• Photosensitivity is manifested by an exaggerated sunburn reaction has been

4 CONTRAINDICATIONS

Because tetracyclines have been shown to depress plasma prothrombin activity.

• Photosensitivity is manifested by an exaggerated sunburn reaction has been

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

5.10 Laboratory Monitoring for Long-Term Therapy

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.

Because tetracyclines have been shown to depress plasma prothrombin activity.